DOAC - Dosing Options in AntiCoagulation Prophylaxis
Launched by UNIVERSITY OF VERMONT · May 26, 2025
Trial Information
Current as of August 20, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, called DOAC - Dosing Options in AntiCoagulation Prophylaxis, is studying how to prevent blood clots in cancer patients who are at moderate risk for developing these clots. Blood clots can cause serious problems, including pain and delays in cancer treatment. The trial will test a blood thinner called apixaban (Eliquis) in two different dosing methods: a standard dose of 2.5 mg taken twice a day and a more convenient dose of 5 mg taken once a day. There will also be a group that receives no blood thinners for comparison. The goal is to see if either of the apixaban doses is effective and safe in reducing blood clots and improving outcomes for patients.
To be eligible for the trial, participants need to be at least 18 years old, have an active solid tumor or lymphoma, and be starting or changing their cancer treatment. They should not be currently taking any blood thinners for other conditions. Over the course of the study, which lasts six months, researchers will monitor participants for any blood clots, serious bleeding, or deaths. This trial is designed to be easy to follow in real-life settings, with medications prescribed through regular healthcare channels, allowing for a smooth transition after the study ends.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- • Diagnosed with an active solid tumor or lymphoma
- • Starting a new systemic cancer treatment or changing cancer treatment
- • Khorana Risk Score of 2 (calculated based on lab and clinical data at treatment initiation)
- • Not currently receiving therapeutic anticoagulation
- • Able to provide informed consent
- Exclusion Criteria:
- • Active bleeding or high risk of bleeding (e.g., recent major surgery, CNS tumors with hemorrhagic risk)
- • Known contraindication to apixaban (e.g., allergy, severe liver disease, dual strong CYP3A4 and P-gp inhibitors)
- • Current therapeutic-dose anticoagulation for VTE or atrial fibrillation
- • Platelet count \< 50,000/µL
- • Creatinine clearance \< 25 mL/min
- • Life expectancy \< 3 months
- • Pregnant or breastfeeding
- • Inability to comply with study procedures
About University Of Vermont
The University of Vermont (UVM) is a leading academic institution known for its commitment to advancing healthcare through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, UVM leverages its diverse expertise in medicine, public health, and biomedical sciences to conduct cutting-edge clinical studies. The university aims to translate scientific findings into effective treatments and interventions, ultimately improving patient outcomes and contributing to the broader medical community. UVM's research facilities and access to a wide patient population support its mission to foster a culture of inquiry and excellence in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Burlington, Vermont, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported